Accelerate Diagnostics Inc (NASDAQ:AXDX) Shorts Decreased by 1.02% After Short Covering

March 18, 2018 - By Ellis Scott

 Accelerate Diagnostics Inc (NASDAQ:AXDX) Shorts Decreased by 1.02% After Short Covering

Investors sentiment decreased to 1.63 in 2017 Q3. Its down 1.37, from 3 in 2017Q2. It dropped, as 15 investors sold Accelerate Diagnostics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 38 raised stakes. 21.32 million shares or 11.33% more from 19.15 million shares in 2017Q2 were reported.
Bancshares Of America De has invested 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Albion Group Incorporated Ut holds 0.2% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) for 58,278 shares. Ameritas Invest Prtn invested in 0% or 2,287 shares. Metropolitan Life Ins has 0% invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Credit Agricole S A holds 0.01% or 188,490 shares. Group One Trading Lp accumulated 0.01% or 37,033 shares. Cutter & Brokerage Incorporated, a Missouri-based fund reported 26,785 shares. Arrowmark Colorado Hldgs Ltd Limited Liability Company holds 860,482 shares. Schwab Charles Inv Management holds 123,537 shares or 0% of its portfolio. Lombard Odier Asset (Usa) Corporation stated it has 25,000 shares or 0.04% of all its holdings. Bokf Na has invested 0.01% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). 28,284 were accumulated by Parametric Port Associate Lc. Citadel Lc holds 29,556 shares. Financial Bank Of New York Mellon owns 126,863 shares. Northern Corp holds 342,142 shares or 0% of its portfolio.

Since October 12, 2017, it had 10 insider purchases, and 0 insider sales for $10.52 million activity.

The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) registered a decrease of 1.02% in short interest. AXDX’s total short interest was 10.81M shares in March as published by FINRA. Its down 1.02% from 10.92M shares, reported previously. With 284,000 shares average volume, it will take short sellers 38 days to cover their AXDX’s short positions. The short interest to Accelerate Diagnostics Inc’s float is 40.45%.

The stock increased 0.99% or $0.25 during the last trading session, reaching $25.45. About 338,903 shares traded or 30.94% up from the average. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has risen 147.12% since March 18, 2017 and is uptrending. It has outperformed by 130.42% the S&P500.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. The company has market cap of $1.42 billion. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. It currently has negative earnings. The firm was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Ratings Coverage

Among 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Accelerate Diagnostics had 9 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by JP Morgan on Tuesday, August 9 with “Overweight”. JP Morgan initiated the stock with “Overweight” rating in Thursday, March 24 report. The stock of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has “Overweight” rating given on Wednesday, December 16 by Piper Jaffray. The rating was maintained by Piper Jaffray on Sunday, September 17 with “Buy”. The company was downgraded on Wednesday, December 13 by BTIG Research. The firm has “Buy” rating by Piper Jaffray given on Thursday, August 3. On Wednesday, July 12 the stock rating was reinitiated by BTIG Research with “Buy”. The firm earned “Neutral” rating on Tuesday, August 25 by BTIG Research. The firm has “Outperform” rating by William Blair given on Friday, January 8.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: